[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cad---coronary-artery-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cad---coronary-artery-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,47,70,100,124,151,181,209,235,257],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100622105","soft-foam-dressings-for-pressure-injury-prevention-of-cardiac-surgery-100622105",false,"NCT07379294","Soft Foam Dressings for Pressure Injury Prevention of Cardiac Surgery","Effectiveness of Using Soft Foam Dressings in Preventing Pressure Injuries During Cardiac Surger","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Scheduled to undergo cardiac surgery under general anesthesia\n* Use of cardiopulmonary bypass (CPB) during surgery\n* Expected surgical duration greater than 4 hours\n* Intact skin without pre-existing pressure injury prior to surgery\n\nExclusion Criteria:\n\n* Surgical position other than supine\n* Long-term bedridden status prior to hospital admission\n* Altered consciousness or inability to cooperate\n* History of stroke with residual limb weakness","ALL","18 Years",{"count":19,"type":20},80,"ESTIMATED","INTERVENTIONAL",[23],"NA","The purpose of this study is to evaluate whether the application of soft foam dressings can reduce the occurrence of surgery-related pressure injuries among patients undergoing cardiac surgery. Specifically, this research aims to investigate differences in pressure injury outcomes before and after the intervention, and to assess the preventive effectiveness of soft foam dressings as an adjunctive skin-protection strategy.",[26,27,28,29,30,31,32,33,34],"CAD - Coronary Artery Disease","CABG","Valve Disease, Heart","Aortic Diseases","Valve Heart Stenosis","Aortic Aneurysm","Mitral Disease","AORTIC VALVE DISEASES","Aortic Dissection","NOT_YET_RECRUITING","2026-05-11",{"date":38,"type":39},"2026-05-14","ACTUAL",{"date":41,"type":20},"2026-05-31",{"date":43,"type":20},"2027-05-30",{"name":45,"class":46},"Shih,Wen-Chi","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":60,"lastUpdatePostDateStruct":61,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":69},"100636718","low-dose-colchicine-for-cabg-graft-failure-prevention-100636718","NCT07569328","Low-dose Colchicine for CABG Graft Failure Prevention","Low-dose Colchicine for CABG Graft Failure Prevention: A Randomized, Double-Blind, Placebo-Controlled Trial","Inclusion Criteria:\n\n1. Be male or female, aged 18 years or older;\n2. Within 3 days after successful isolated coronary artery bypass grafting (CABG);\n3. Sign informed consent;\n\nExclusion Criteria:\n\n1. Severe valvular heart disease requiring concomitant or staged valvular surgery;\n2. History of non-skin cancer in the past 3 years;\n3. Inflammatory bowel disease or chronic diarrhea;\n4. Neuromuscular diseases or non-transient creatine kinase levels greater than 3 times the upper limit of the normal range (except those associated with myocardial infarction);\n5. Clinically significant non-transient (At least 2 laboratory tests) blood abnormalities (Hemoglobin \\\u003C100g\u002FL or hematocrit \\\u003C 30% or \\> 52% or white blood cell count \\\u003C 3×109\u002FL or platelet count \\\u003C 100×109\u002FL);\n6. Estimated glomerular filtration rate (eGFR) \\\u003C 30 mL\u002Fmin\u002F1.73 m² (based on the CKDEPI formula);\n7. Serum alanine aminotransferase and\u002For aspartate aminotransferase levels greater than 2 times the upper limit of the normal range, accompanied by serum total bilirubin levels greater than 2 times the upper limit of the normal range or severe liver disease with coagulation disorders (INR\\>1.5) (except for elevated glutamic oxalacetic transaminase associated with myocardial infarction);\n8. Decline in cognitive function due to inability to perform basic activities of daily living independently;\n9. Drug or alcohol abuse;\n10. Other immunosuppressive therapies already in existence or planned;\n11. Other causes require long-term colchicine treatment;\n12. History of clear or suspected colchicine allergy;\n13. Strong CYP3A4 or P-glycoprotein inhibitors (such as cyclosporine, antiretrovirals, antifungals, erythromycin and clarithromycin) have been used and no other alternative drugs can be used.",{"count":55,"type":20},622,[23],"This study aims to evaluate whether daily low-dose colchicine (0.5 mg), administered in addition to the standard secondary prevention regimen recommended in clinical guidelines after coronary artery bypass grafting (CABG), can further prevent graft failure after CABG through a prospective, randomized, double-blind, placebo-controlled clinical trial.",[26,27,59],"Colchicine","2026-04-29",{"date":62,"type":39},"2026-05-06",{"date":64,"type":20},"2026-09-01",{"date":66,"type":20},"2029-09-01",{"name":68,"class":46},"Beijing Anzhen Hospital",1,{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":80,"phases":4,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":69},"100629918","risk-stratification-of-mace-in-heart-failure-patients-who-undergoing-cabg-100629918","NCT07480915","Risk Stratification of MACE in Heart Failure Patients Who Undergoing CABG","Risk Stratification of MACE Based on GDF-15 in Heart Failure Patients Who Undergoing Coronary Artery Bypass Grafting: an Observational Multicenter Prospective Study","PROFILE-HF","Inclusion Criteria:\n\n* Heart Failure\n* Planned coronary artery bypass grafting\n\nExclusion Criteria:\n\n* Myocardial infarction\n* Stroke\n* Presence of implanted devices;\n* Need for additional cardiac surgery other than coronary artery bypass grafting (valve repair, aneurysm);\n* Severe renal dysfunction (GFR \\\u003C30 ml\u002Fmin\u002F1.73 m2);\n* Severe comorbidities: active cancer; infiltrative cardiac diseases (sarcoidosis, amyloidosis, storage diseases); autoimmune diseases; acute infectious diseases and exacerbations of chronic somatic diseases.",{"count":79,"type":20},160,"OBSERVATIONAL","PROFILE-HF is a multicenter, observational, prospective study of the clinical course and outcomes of chronic heart failure (HF) and coronary artery disease (CAD) in patients undergoing coronary artery bypass grafting (CABG).\n\nThe objective of the study is to develop a method for assessing the risk of adverse cardiovascular events in patients with CAD and HF who have undergone CABG, based on preoperative GDF-15 concentrations.\n\nThe study will have a 12-month follow-up period; one in-person visit is planned at the end of the follow-up period. If it is not possible to visit a doctor in person, information will be collected through telephone contact with the patient or his relative or person caring for the patient.",[83,26,27],"Heart Failure",[83,85,27,86,87,88,89],"Coronary Artery Disease","Coronary Artery Bypass Grafting","GDF-15","Growth differentiation factor - 15","Prognosis","RECRUITING","2026-03-13",{"date":93,"type":39},"2026-03-18",{"date":95,"type":39},"2026-03-04",{"date":97,"type":20},"2028-03",{"name":99,"class":46},"Tomsk National Research Medical Center of the Russian Academy of Sciences",{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":4,"eligibilityCriteria":106,"healthyVolunteers":107,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":108,"targetDuration":110,"studyType":80,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":116,"startDateStruct":118,"completionDateStruct":120,"leadSponsor":122,"locationsCount":69},"100627686","chronic-total-occlusion-and-triglyceride-glucose-index-100627686","NCT07451860","Chronic Total Occlusion and Triglyceride-Glucose Index","The Role of the Triglyceride-Glucose Index in Determining the Risk of Chronic Total Occlusion in Coronary Artery Disease","Inclusion Criteria:\n\n* Adults ≥18 years of age, patients undergoing coronary angiography, non-obese individuals\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years of age, history of atrial fibrillation, pacemaker implantation, asthma, pulmonary hypertension, pregnancy, anemia, malignancy, rheumatoid arthritis, or peripheral artery disease, obesity (BMI \\>30 kg\u002Fm²), inaccessible patient records",true,{"count":109,"type":20},200,"1 Day","We retrospectively analyzed 200 CAD patients undergoing coronary angiography between 2026-2027. Patients were grouped by CTO presence. Clinical and laboratory parameters were compared, and logistic regression was performed to identify independent predictors.",[26,113,114],"Chronic Total Occlusion (CTO)","Triglycerid Glucose Index","2026-02-28",{"date":117,"type":39},"2026-03-05",{"date":119,"type":20},"2026-03-15",{"date":121,"type":20},"2026-09-15",{"name":123,"class":46},"Kırıkkale University",{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":130,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":132,"enrollmentInfo":133,"targetDuration":4,"studyType":21,"phases":135,"briefSummary":136,"conditions":137,"keywords":139,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":115,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":148,"locationsCount":69},"100627660","comparative-analysis-of-analgesic-approaches-in-the-early-period-after-cabg-100627660","NCT07451522","Comparative Analysis of Analgesic Approaches in the Early Period After CABG","Comparative Characteristics of Analgesia Methods in the Early Postoperative Period After Coronary Artery Bypass Grafting (CABG)","CABG-PAIN","Inclusion Criteria:\n\n* ASA score less then 3, Signed inform consent, Absence of preoperative drugs administration that affects patient's perception of pain, No active infection process, BMI index \\>18,5 kg\\\\m2 and \\\u003C 35 kg\u002Fm2, CABG, Age 18-75 years\n\nExclusion Criteria (the presence of at least one is sufficient):\n\n* Failure to meet the inclusion criteria.\n* High severity according to ASA (class IV or higher), which is associated with a high probability of prolonged mechanical ventilation, hemodynamic instability, and inability to use drugs affecting cardiac output and\u002For total peripheral vascular resistance.\n* Contraindications to the use of tafalgin and\u002For morphine in accordance with the approved Summary of Product Characteristics (hypersensitivity to tafalgin, morphine, other opioids, or any excipients).\n* Pregnancy or lactation.\n* Acute or prolonged chronic intoxication with drugs or substances depressing the central nervous system (alcohol, barbiturates, opioid drugs, benzodiazepines).\n* Use of monoamine oxidase inhibitors (MAOIs) or less than 14 days since their discontinuation.\n* Liver cirrhosis, Child-Pugh class C.\n* Acute renal failure requiring renal replacement therapy.\n* Unresected malignant neoplasm.\n* Mesenteric thrombosis or another severe abdominal pain syndrome of unclear etiology at the time of inclusion.\n* Simultaneous participation in another clinical study.\n* Marked CNS depression due to any cause, except for acute poisoning.\n* COPD stage III and\u002For bronchial asthma in the exacerbation phase.\n* Any clinically significant condition, disease, or circumstance in the medical history that, in the opinion of the investigator, precludes participation in the study.\n* Psychiatric, physical, or other conditions preventing adequate assessment of the patient's behavior or proper compliance with the study protocol.\n* Postoperative hemodynamic instability requiring high-dose inotropic and\u002For vasopressor support (epinephrine \\> 0.1 μg\u002Fkg\u002Fmin, dopamine \\> 10 μg\u002Fkg\u002Fmin, norepinephrine \\> 0.2 μg\u002Fkg\u002Fmin) and\u002For mechanical circulatory support.\n* Refusal to participate in the study.","75 Years",{"count":134,"type":20},100,[23],"The goal of this clinical trial is to study postoperative analgesia in patients undergoing CABG. And learn if tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) treats pain not inferiory then morphine. The main questions it aims to answer are:\n\nDoes tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) lower the VAS score same way as a morphine? What medical problems do participants have when taking tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid)?\n\nParticipants will:\n\nGroup (1)- subcutaneous single dose of morphine 10 mg would be administred based on VAS score \\> 3 during 24 hours after CABG.\n\nExprimental group (2)- subcutaneous single dose of tafalgin (tyrosyl-D-arginyl-phenylalanyl-glycine amid) - 0.4 mg would be administred based on VAS score \\> 3 during 24 hours after CABG.\n\nEfficacy was assessed using the VAS scale decreassion. Hemodynamic parameters and arterial blood gases were also assessed.",[26,27,138],"Analgesia Assessment",[27,140,141,142,143],"CAD","Morphine","Tafalgin","VAS",{"date":117,"type":39},{"date":146,"type":39},"2025-12-01",{"date":119,"type":20},{"name":149,"class":150},"Primorsky Regional General Hospital #1","OTHER_GOV",{"id":152,"slug":153,"hasResults":11,"nctId":154,"briefTitle":155,"officialTitle":156,"acronym":157,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":159,"targetDuration":4,"studyType":21,"phases":161,"briefSummary":162,"conditions":163,"keywords":167,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":173,"completionDateStruct":175,"leadSponsor":177,"locationsCount":180},"100621308","advanced-nanotherapies-dual-api-dcb-to-treat-de-novo-and-isr-lesions-in-patients-with-symptomatic-coronary-artery-disease-100621308","NCT07368933","Advanced NanoTherapies Dual-API DCB to Treat De-Novo and ISR Lesions in Patients With Symptomatic Coronary Artery Disease","ADVANCEd NanoTherapies SirPlux Duo™ Dual API-Coated PTCA Balloon Catheter to Treat Coronary In-stent Restenosis (ISR) and de Novo Lesions","ADVANCE-DUO","Inclusion Criteria:\n\n1. ≥18 years or minimum legal age as required by local regulations.\n2. Documented stable or unstable angina, positive functional test, or non -ST elevation myocardial infarction which, in the judgment of the operator, is attributable to disease in coronary vessel or in-stent restenosis, and the patient is deemed an appropriate candidate for PCI in accordance with the applicable guidelines on percutaneous coronary intervention.\n\n   Note: participants with NSTEMI must have enzymes that are trending down or are within normal limits prior to enrollment.\n3. Life expectancy \\>1 year in the Investigator's opinion.\n4. Participant is willing and able to cooperate with study procedures and follow-up evaluations.\n5. Treatment of only one target lesion required\n\n   1. Tandem lesions treated by a single DCB will be considered one target lesion.\n   2. Up to one de novo lesion in a separate vessel may be treated per standard of care at the procedure. Non-target lesions must be successfully treated under the same criteria of the target lesion, before treating the target lesion.\n6. Target lesion must be ≤36 mm in length.\n7. Target lesion must have a stenosis ≥ 50% and \\\u003C 100%.\n8. Target lesion must have a visually estimated reference vessel diameter of:\n\n   1. ISR lesions: 2.0 to 4.0 mm in diameter (inclusive)\n   2. de novo lesions: 2.0 to \\\u003C3.0 mm in diameter\n9. ISR lesions only: target lesion must be within a previous BMS or DES that does not extend \\>5.0 mm beyond the proximal or distal edge.\n\nExclusion Criteria:\n\n1. Participant is pregnant, or breastfeeding. Note: Participant of childbearing potential must have a negative pregnancy test within 7 days before procedure.\n2. Known hypersensitivity or contraindication to antiplatelet medications (e.g., aspirin; heparin; prasugrel); or a sensitivity to contrast media which cannot be adequately pre-medicated.\n3. History of an allergic reaction or significant sensitivity to paclitaxel, sirolimus, or any other analogue or derivative.\n4. Platelet count \\\u003C 100,000 cells\u002Fmm³ (i.e., 100 x 109 \u002FL) or \\> 700,000 cells\u002Fmm³ (i.e., 700 x 10 9 \u002FL), or a white blood cell (WBC) count \\\u003C 3,000 cells\u002Fmm³ within 7 days prior to procedure.\n5. Renal insufficiency (Serum creatinine level \\> 2.5 mg\u002Fdl (i.e., 221 μmol\u002FL) within 7 days prior to procedure) or failure (dialysis dependent).\n6. Evidence of an acute MI within 72 hours of the procedure Note: participants with NSTEMI are allowed, provided enzymes are trending down or are within normal limits prior to enrollment.\n7. Previous PCI of the target vessel within 6 months prior to procedure.\n8. History of a stroke or transient ischemic attack (TIA) within the prior 3 months to procedure (any prior stroke or TIA, if prasugrel is used).\n9. Planned PCI of any vessel within 30 days post-procedure and\u002For planned PCI of the target vessel within 12 months post-procedure.\n10. Active peptic ulcer or upper gastrointestinal (GI) bleeding within the prior 6 months to procedure.\n11. History of bleeding diathesis or coagulopathy or will refuse blood transfusions.\n12. Documented left ventricular ejection fraction (LVEF) \\\u003C30% at the most recent evaluation, within the prior 3 months to procedure.\n13. Planned surgery that would cause interruption in recommended DAPT duration per current guidelines.\n14. Currently participating in an investigational drug or another device study that has not completed the primary endpoint or that clinically interferes with the current study endpoints; or requires additional coronary angiography, IVUS, or other coronary artery imaging procedures.\n15. The following criteria related to previous treatments applies based on the type of lesion treated. The participant is excluded in the following circumstances:\n\n    1. ISR lesions: If single-layer ISR, any previous treatment of the target vessel for restenosis. If double- layer ISR, any treatment of the double-layer ISR.\n    2. de novo lesions: any previous treatment of the target lesion.\n16. Planned PCI of three vessel disease during procedure.\n17. Planned treatment of more than one target vessel. Tandem lesions that can be treated by a single DCB are permissible.\n18. Target lesion requires treatment with atherectomy, laser, or thrombectomy procedure.\n19. Target vessel has other lesions with greater than 50% diameter stenosis based on visual estimate.\n20. Target vessel has evidence of thrombus.\n21. Target vessel is excessively tortuous, defined as more than one bend \\>90° to reach target lesion.\n22. Target lesion has any of following characteristics:\n\n    1. Lesion location is unprotected in left main coronary artery, internal mammary artery, aorto-ostial, bypass grafts, ostial lesions or within 5 mm of the origin of the left anterior descending or left circumflex.\n    2. Involves a side branch \\>2.0 mm in diameter.\n    3. Is severely calcified.\n23. The following criteria based on number and type of lesions:\n\n    1. ISR and de novo lesions: target lesion is in the same vessel with a de novo lesion requiring treatment.\n    2. ISR lesions: planned treatment of a ≥3 layer ISR lesion.",{"count":160,"type":20},30,[23],"The study objectives are:\n\n1. To evaluate the safety and performance of the SirPlux Duo PTCA to treat coronary ISR lesions 2.00-4.00 mm (inclusive) in diameter in patients with symptomatic coronary artery disease.\n2. To evaluate the safety and performance of the SirPlux Duo PTCA to treat coronary de novo lesions \\\u003C3.00 mm in diameter in patients with symptomatic coronary artery disease.",[164,26,165,166],"Angina (Stable)","Unstable Angina","NSTEMI - Non-ST Segment Elevation MI",[168,169,85],"DCB","Drug Coated Balloon","2026-01-23",{"date":172,"type":39},"2026-01-27",{"date":174,"type":39},"2025-12-15",{"date":176,"type":20},"2029-01",{"name":178,"class":179},"Advanced NanoTherapies","INDUSTRY",3,{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":190,"briefSummary":192,"conditions":193,"keywords":197,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":200,"lastUpdatePostDateStruct":201,"startDateStruct":203,"completionDateStruct":205,"leadSponsor":207,"locationsCount":69},"100615461","phase-4-effect-of-empagliflozin-on-inflammation-100615461","NCT07292909","Effect of Empagliflozin on Inflammation","Randomized Trial to Evaluate the Anti-inflammatory Effects of Empagliflozin Following PCI","EMPANTINFLAM","Inclusion Criteria:\n\n* • Patients with stable CAD who are electively scheduled for PCI on a de novo lesion in a native coronary artery\n\nExclusion Criteria:\n\n* • Patients who have been taking an SGLT-2 inhibitor during the last month\n\n  * Patients who are receiving any anti-inflammatory medication: immunosuppressor, steroids, NSAID…\n  * Patients who have underlying inflammatory conditions such as rheumatic arthritis, infection, active malignancy\n  * Patients with an acute coronary syndrome within the last month\n  * Intervention on a restenotic lesion or lesion in a saphenous vein graft\n  * Creatinine clearance less than 30 mL\u002Fmin\n  * Patients who are treated with devices other than balloons and stents (lithotripsy, rotational atherectomy…)",{"count":134,"type":20},[191],"PHASE4","Empagliflozin is a drug given to lower glucose. It is used in the treatment of diabetes. However, it was shown to improve symptoms and survival of patients who are suffering from heart failure. The exact mechanism of this effect is currently not clearly understood.\n\nHe hypothesize that empagliflozin has other properties than glucose lowering, that can explain its efficacy. One of these properties, is an anti-inflammatory effect.\n\nTo document this, we are using a model of inflammation following percutaneous coronary scenting. We know that patients who get a stent will develop inflammation following stenting. This is documenting by a higher level of C-Reactive Protein 24 hours after the procedure.\n\nPatients who will participate in the study, will receive empagliflozin or a placebo tablet for 3 days prior to the revascularisation procedure. CRP and other inflammatory markers will be measured before intervention and 24 hours later. The goal is to demonstrate a lower rise in CRP following intervention in patients treated with empagliflozin vs. those who have received a placebo.",[26,194,195,196],"Inflamation","PCI","SGLT 2 Inhibitors",[140,198,199],"inflammation","SGLT2 inhibitors","2025-12-06",{"date":202,"type":39},"2025-12-18",{"date":204,"type":39},"2025-09-01",{"date":206,"type":20},"2027-09-30",{"name":208,"class":46},"Hotel Dieu de France Hospital",{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":215,"eligibilityCriteria":216,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":217,"targetDuration":219,"studyType":80,"phases":4,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":69},"100610765","registry-of-coronary-disease-outcomes-revascularizing-with-drug-coated-balloons-100610765","NCT07231835","Registry of Coronary Disease Outcomes Revascularizing With Drug-Coated Balloons","RECORD-DCB: Registry of Coronary Disease Outcomes Revascularizing With Drug-Coated Balloons","RECORD-DCB","Inclusion Criteria:\n\n* Patients undergoing PCI with the Protégé paclitaxel-eluting DCB\n* Age ≥ 18 years\n* Presence of a de novo lesion or in-stent restenosis in a native coronary artery or a in a bypass graft and suitable for PCI\n* Reference vessel diameter between 2.0 - 4.5 mm\n* Patient suitable for dual antiplatelet therapy (DAPT)\n\nExclusion Criteria:\n\n* Inability to provide informed consent\n* Allergy to paclitaxel",{"count":218,"type":20},3000,"5 Years","The primary aim of this registry is to systematically collect and analyze real-world data on all patients undergoing PCI with the Protégé paclitaxel-eluting DCB to evaluate procedural outcomes, long-term efficacy, and safety across various clinical indications. This registry aims to assess the clinical effectiveness of DCB therapy across diverse patient populations, including those with stable coronary artery disease (CAD) and acute coronary syndromes (ACS), as well as various lesion subsets, encompassing (but not limited to) in-stent restenosis (ISR), de novo coronary lesions, small vessel disease, bifurcation and calcified lesions, coronary bypass graft lesions, and patients at high risk of bleeding. Additionally, the study aims to identify predictors of success, complications, and optimal treatment strategies to further refine the use of DCBs.",[222,169,223,26,224,225],"Percutaneous Coronary Intervention (PCI)","Paclitaxel","ACS (Acute Coronary Syndrome)","Stable Coronary Artery Disease (CAD), Myocardial Infarction","2025-11-14",{"date":228,"type":39},"2025-11-17",{"date":230,"type":39},"2025-11-11",{"date":232,"type":20},"2034-09-30",{"name":234,"class":46},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":243,"targetDuration":245,"studyType":80,"phases":4,"briefSummary":246,"conditions":247,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":248,"lastUpdatePostDateStruct":249,"startDateStruct":251,"completionDateStruct":253,"leadSponsor":255,"locationsCount":4},"100585222","registry-of-paclitaxel-coated-drug-eluting-balloon-in-all-comers-patients-100585222","NCT06899555","REgistry of Paclitaxel Coated Drug Eluting Balloon in All Comers PaTients","REgistry of Paclitaxel Coated Drug Eluting Balloon in All Comers PaTients (REPEAT Registry)","REPEAT","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patients with symptomatic coronary artery disease (including those with acute coronary syndromes or Chronic Coronary Syndromes) with either symptoms and\u002For ischaemia.\n* The patient must be able to understand and provide informed consent and comply with all study procedures.\n\nCoronary angiographic inclusion criteria:\n\n* ≥70% target lesion stenosis in LAD, LCX or RCA (or branches) which after successful pre-dilatation\\* has a residual stenosis ≤ 30% and no dissection of Type C or greater than (NHLBI guidelines)\n\n  \\*pre-dilation permitted with SC or NC balloon catheter, cutting\u002Fscoring balloon, rotational\u002Forbital atherectomy, or laser\n* Target vessel reference diameter between 2.0 and 4.5 mm.\n\nExclusion Criteria:\n\n* Left ventricular ejection fraction (LVEF) ≤ 30%\n* Acute ST elevation MI (STEMI)\n* Cardiogenic shock within 2 days prior to the index PCI.\n* Known contraindication or hypersensitivity to paclitaxel, and\u002For to any anti-thrombotic and anti-platelet class of drugs\n* Allergy to imaging contrast media which cannot be adequately pre-medicated.\n* Patient undergoing planned surgery within 3 months with the necessity to stop dual antiplatelet therapy (DAPT).\n* Patient is pregnant or breast feeding.\n* Patient has received a heart transplant.\n* Patient is unwilling or unable to give follow-up until study completion.\n* Patient is currently participating in another trial.\n* Life expectancy \\\u003C1 year.\n\nAngiographic exclusion criteria:\n\n* Target lesion in the left main coronary artery.\n* Flow limiting target vessel thrombus\n* Vessel dissection requiring bailout stenting.",{"count":244,"type":20},500,"1 Year","A post marketing, observational , multi centre, prospective registry to assess safety and performance of the Drug Eluting Balloon in patients undergoing percutaneous coronary intervention.\n\nRational : Although DEBs are generally considered safe, there remain many unanswered questions about DEB technology in a real-world population and only limited trial data from geographically or clinically diverse patient subgroups. To address some of the clinical and translational gaps in knowledge we thus plan a clinical registry to assess safety and performance of a novel design of a drug eluting\n\nA real-world, all-comers coronary artery disease (CAD) population undergoing percutaneous coronary intervention (PCI) and suitable for treatment with a Paclitaxel Coated Coronary Balloon Dilatation Catheter.\n\nStudy Population - 500 Patients",[26],"2025-03-21",{"date":250,"type":39},"2025-03-28",{"date":252,"type":20},"2025-05",{"date":254,"type":20},"2027-05",{"name":256,"class":46},"Craigavon Area Hospital",{"id":258,"slug":259,"hasResults":11,"nctId":260,"briefTitle":261,"officialTitle":262,"acronym":263,"eligibilityCriteria":264,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":265,"targetDuration":267,"studyType":80,"phases":4,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":69},"100566846","establishment-of-a-cohort-for-continuous-coronary-artery-cta-scanning-and-predictive-analysis-of-plaque-progression-100566846","NCT06660485","Establishment of a Cohort for Continuous Coronary Artery CTA Scanning and Predictive Analysis of Plaque Progression","Establishment of a Cohort for ConTinuous COronary CTA SCanning And PredicTive Analysis of Plaque Progression (TOCCATA)","TOCCATA","Inclusion Criteria:\n\nPatients who have undergone multiple consecutive CCTA examinations.\n\nExclusion Criteria:\n\nPatients who have undergone only a single CCTA examination. Patients whose CCTA image quality is poor and cannot be analyzed.",{"count":266,"type":20},5000,"2 Years","This research develops risk prediction models for coronary artery stenosis and vulnerable plaques. The coronary artery stenosis model aims to predict stenosis using multimodal deep learning by integrating text, structured numerical data, and imaging features, focusing on metrics like maximum and cumulative stenosis. The vulnerable plaque model seeks to identify early formation indicators, allowing for timely interventions to prevent plaque rupture, using similar data integration techniques. Additionally, a decision support system is created, comprising a patient database, risk prediction models, and a high-risk alert module. This system facilitates real-time notifications to healthcare providers when risk thresholds are exceeded, enabling personalized treatment planning and improved patient outcomes.",[26],"2024-10-25",{"date":272,"type":39},"2024-10-28",{"date":274,"type":20},"2024-10-30",{"date":276,"type":20},"2026-07-01",{"name":278,"class":46},"West China Hospital"]